Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors

Archit B. Baskaran, Ankush Bhatia, Priya Kumthekar, Adrienne Boire, Rimas V. Lukas

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Aims/purpose: Leptomeningeal metastases (LM) are associated with substantial morbidity and mortality. Several approaches are used to treat LM, including intrathecally administered therapies. We consolidated current studies exploring intrathecal therapies for LM treatment. Patients & methods: A review of clinical trials using intrathecal agents was conducted with outcomes tabulated and trends described. 48 trials met the inclusion criteria. Initial investigations began with cytotoxic agents; following this were formulations with longer cerebrospinal fluid half-lives, targeted antibodies and radionucleotides. Results & conclusion: Outcomes were not reported consistently. Survival, when reported, remained poor. Intrathecal therapies for LM remain a viable option. Their use can be informed by an understanding of efficacy, safety and toxicity. They may be an important component of future LM treatments.

Original languageEnglish (US)
Pages (from-to)1801-1807
Number of pages7
JournalFuture Oncology
Volume19
Issue number26
DOIs
StatePublished - Aug 1 2023

Keywords

  • CSF
  • chemotherapy
  • intrathecal
  • leptomeningeal metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors'. Together they form a unique fingerprint.

Cite this